Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement C5

Complement C5

Brief Information

Name:Complement C5
Target Synonym:C5a,Complement Component 5,ECLZB,Anaphylatoxin C5a Analog,C5a Anaphylatoxin,C5b,C5,Prepro-C5,CPAMD4,Complement C5,C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4,C5D
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CO5-H52Hx-ELISA
Human Complement C5 (R885H), His TagHuman Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) ELISA bioactivity

Immobilized Human Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

CO5-H52H7-ELISA
Human Complement C5 (w917s), His TagHuman Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) ELISA bioactivity

Immobilized Human Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) at 2 μg/mL (100 μL/well) can bind Anti-C5a MAb (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

Synonym Name

Complement C5,C5,CPAMD4

Background

Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Eculizumab 5G1-1; HAL-1; LEX-98; h-5G1.1 Approved Alexion Pharmaceuticals Inc Soliris Mainland China Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal Alexion Europe Sas 2007-03-16 Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Neuromyelitis Optica; Asthma; Guillain-Barre Syndrome Details
Ravulizumab ALXN-1810; ALXN-1210 Approved Alexion Pharmaceuticals Inc, Xencor Inc Ultomiris United States Atypical Hemolytic Uremic Syndrome Alexion Pharmaceuticals Inc 2018-12-21 Myasthenia Gravis; Dermatomyositis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Coronavirus Disease 2019 (COVID-19); Atypical Hemolytic Uremic Syndrome; Thrombotic Microangiopathies; Respiratory Distress Syndrome, Adult; Lupus Nephritis; Neuromyelitis Optica; Pneumonia, Viral; Acute Lung Injury; Amyotrophic Lateral Sclerosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ALXN-5500 ALXN-5500 Phase 1 Clinical Alexion Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
Avacincaptad pegol ARC-187; ARC-1905 Phase 3 Clinical Archemix Geographic Atrophy; Stargardt Disease; Macular Degeneration Details
Tesidolumab NOV-4; LFG-316 Phase 2 Clinical Novartis Pharma Ag, Morphosys Ag Rejection of renal transplantation; Hemoglobinuria, Paroxysmal; Wet Macular Degeneration; Geographic Atrophy; Macular Degeneration Details
Eculizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Hemoglobinuria, Paroxysmal Details
Olendalizumab ALXN-1007 Phase 2 Clinical Alexion Pharmaceuticals Inc Graft vs Host Disease; Antiphospholipid Syndrome; Rejection of organ transplantation; Inflammation Details
Eculizumab biosimilar (Biocad) BCD-148 Phase 3 Clinical Biocad Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (IBC GENERIUM) Phase 3 Clinical Ibc Generium Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Eculizumab biosimilar (Samsung Bioepis) SB-12 Phase 3 Clinical Samsung Bioepis Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (Amgen) ABP-959 Phase 3 Clinical Amgen Inc Hemoglobinuria, Paroxysmal; Hemolytic-Uremic Syndrome Details
eculizumab biosimilar(Isu Abxis) Phase 1 Clinical Isu Abxis Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Nomacopan EV-576; rVA576; rEV-576 Phase 3 Clinical Evolutec Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Keratoconjunctivitis Details
Zilucoplan RA-101495-SC; RA-101495 Phase 3 Clinical Ucb Sa, Ra Pharma Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Lupus Nephritis; Hemolytic-Uremic Syndrome Details
ALXN-1720 ALXN-1720 Phase 1 Clinical Alexion Pharmaceuticals Inc Details
Vilobelimab IFX-1; CaCP-29 Phase 3 Clinical Beijing Mabworks Biotech Co Ltd, Inflarx Nv Granulomatosis with Polyangiitis; Drug-Related Side Effects and Adverse Reactions; Shock, Septic; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Microscopic Polyangiitis; Pyoderma Gangrenosum; Coronavirus Disease 2019 (COVID-19); Sepsis; Lung Diseases, Interstitial; Systemic Inflammatory Response Syndrome; Hidradenitis Suppurativa Details
Crovalimab SKY-59; RG-6107; CH-7092230; RO-7092230; RO-7112689; RO-7112689/F01 Phase 3 Clinical F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Anemia, Sickle Cell Details
CAN-106 CAN-106 Phase 2 Clinical Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn Details
Pozelimab REGN-3918 Phase 3 Clinical Regeneron Pharmaceuticals Inc Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies Details
Cemdisiran ALN-62643; ALN-CC5; AD-62643 Phase 3 Clinical Alnylam Pharmaceuticals Inc Myasthenia Gravis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Hemolytic-Uremic Syndrome Details
BDB-001 BDB-001; BDB001; BDB 001; BDB-1 Phase 3 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Solid tumours; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message